CORCEPT THERAPEUTICS INC Proceeds from Debt, Net of Issuance Costs
CORCEPT THERAPEUTICS INC (CORT) reported Proceeds from Debt, Net of Issuance Costs of $29.86 million for the 12-month period ending 2012-12-31, per its 10-K filed 2015-03-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2015-03-13
- CORCEPT THERAPEUTICS INC proceeds from debt, net of issuance costs for the quarter ending 2012-12-31 was $0.00.
- CORCEPT THERAPEUTICS INC proceeds from debt, net of issuance costs for fiscal 2012 was $29.86M.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $29.86M 10-K · filed 2015-03-13 | |
| 2012-09-30 | $29.86M 10-Q · filed 2013-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |